Researchers from the Mass General Cancer Center have shown that mutations in a gene regulating basal epithelial cells may play a significant role in the development of breast cancer.
Departments, Centers, & Programs:
Massachusetts General Hospital
55 Fruit Street
Boston, MA 02114-2696
- MD, PhD, Stanford University School of Medicine
- Residency, Brigham and Women's Hospital
- Fellowship, Dana Farber Cancer Institute
American Board Certifications
- Medical Oncology, American Board of Internal Medicine
Accepted Insurance Plans
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
In the Ellisen Laboratory, scientists identify genetic abnormalities in tumor cells that are not present in normal tissues, study how the abnormalities influence the biology of cancer cells, and explore how their new discoveries can inform the selection of the most effective therapy for each patient. Key tumor cell pathways under investigation in the laboratory include p53, BRCA1/2, and mTOR. Dr. Ellisen is best known for his work on triple-negative breast cancer (TNBC), one of the most aggressive forms of the disease. His research has shown that a chemotherapy drug used to treat several other types of cancer - but rarely breast cancer - holds promise for TNBC patients. Dr. Ellisen now oversees clinical trials of this and many other promising new therapies in breast cancer.